Folisurge 75 Injection contains recombinant follicle stimulating hormone (FSH) at a strength of 75 IU, designed to support and stimulate ovarian follicular development in women undergoing assisted reproductive technologies such as in vitro fertilization (IVF) or ovulation induction. FSH is a naturally occurring hormone essential for the growth and maturation of ovarian follicles, which contain the eggs. By administering Folisurge 75 Injection, clinicians can promote controlled ovarian stimulation, increasing the chances of successful ovulation and fertilization. This medication is typically used in women with anovulation or oligo-ovulation, including those with polycystic ovary syndrome (PCOS), or in patients undergoing assisted reproductive procedures. The recombinant nature of the hormone ensures high purity and consistent biological activity, minimizing the risk of immunogenic reactions compared to urinary-derived products. Folisurge 75 Injection is administered subcutaneously or intramuscularly, with dosage and duration tailored by a healthcare professional based on individual patient response and treatment protocols. Common side effects may include mild injection site reactions, headache, or ovarian hyperstimulation syndrome (OHSS) in rare cases. Proper monitoring by a fertility specialist is essential to optimize treatment outcomes and minimize adverse effects.